Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML
暂无分享，去创建一个
H. Kantarjian | G. Garcia-Manero | Xuelin Huang | K. Patel | T. Kadia | F. Ravandi | G. Borthakur | N. Daver | C. Dinardo | N. Short | J. Matthews | G. Montalban-Bravo | W. Qiao | G. Issa | K. Chien | M. Yilmaz | L. Nasr | W. Macaron | J. Thankachan | R. Abramova | E. Jabbour | Cedric Nasnas | Marina Y Konopleva | Christopher J Stojanik